Press Releases

73 abstracts presented at ASCO with 19 related to Lynparza and new potential medicines targeting DNA damage response in multiple tumour typesContinued momentum of immuno-oncology medicines including new data on durvalumab in bladder cancer, underpinning the Breakthrough Therapy Designation,...

Data presentations further evaluate HUMIRA® (adalimumab) for the treatment of inflammatory bowel diseases including moderate to severe Crohn's disease in adult and pediatric patients. Late-breaking Phase 2 data evaluates risankizumab, an anti-IL-23 monoclonal biologic antibody for...

Bayer announced that data from several studies across its oncology portfolio will be presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place June 3-7 in Chicago, Illinois (USA). The...

Subjects received one-time administration of a highly optimized gene therapy at initial low dose without the need for immunosuppression Therapeutic Factor IX activity sustained at levels exceeding those considered sufficient to reduce the risk of joint bleeds and...

14 avelumab abstracts at ASCO 2016 highlight significant progress being made by the collaboration between Merck KGaA, Darmstadt, Germany, and Pfizer Two oral presentations: avelumab investigated as a second-line treatment for metastatic Merkel cell carcinoma and in advanced...

Final Overall Survival Data from KEYNOTE-006 To Be Presented at ASCO; KEYTRUDA, the First Anti-PD-1 Monotherapy to Demonstrate Overall Survival Compared to Ipilimumab, Shows Continued Benefit with Longer Follow-Up. KEYNOTE-001 Findings Show Continued Benefit in Response...

GlaxoSmithKline and Innoviva, Inc announced that GlaxoSmithKline plc (GSK) presented new data at the American Thoracic Society (ATS) Conference from two pre-specified analyses from the Study to Understand Mortality and MorbidITy (SUMMIT) trial. One demonstrated that...